REQUEST E-APPLICATION FORM | 01244 746000 | Log in
Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.
Investments in unquoted companies carry high risks and investors could lose all funds invested. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. Investors are encouraged to take independent legal, tax and financial advice before considering an investment.
By clicking below, you confirm that you are an FCA authorised firm or individual and agree to be directed to our website, which is for FCA authorised firms and individuals only. Persons who do not meet this classification should leave this page.
If you are not a professional financial adviser, please contact the Deepbridge Investor Relations Team on 01244 746000 or by email at enquiries@deepbridgecapital.com.
Deepbridge is delighted to commit £1m to a £2.25m funding round by existing investee company Liverpool ChiroChem. We are pleased to be joined by funding partners from Praetura Ventures and NPIF - Maven Equity Finance, which is managed by Maven and part of the Northern Powerhouse Investment Fund, as part of the funding round.
Picturepath, which is part of the Deepbridge Life Sciences EIS fund, is aiming to help autistic children during lockdown through an online app that founder, Richard Nurse, originally created for his son with the aim to reduce his anxiety.
Elasmogen, which is part of the Deepbridge Life Sciences EIS portfolio, have announced a collaboriation with Intract Pharma Limited London, to discover and develop novel orally-delivered protein therapeutics, which will incorporate proprietary technologies developed by each company.
Caroline Barelle, CEO of Elasmogen commented:
Last year, arbnco, which is part of the Deepbridge Technology Growth EIS portfolio, announced a collaboration with Arc Skoru Inc. to help rate the operational performance of buildings through indoor environmental monitoring.
We are pleased to announce that VoxSmart, which is part of the Deepbridge Technology Growth EIS portfolio, has been classified as 'enterprise critical' and essential for business continuity by the financial institutions in the Asia Pacific (APAC) region during the worldwide pandemic. VoxSmart’s services and technology support many clients in the APAC
Elasmogen, which is part of the Deepbridge Life Sciences EIS portfolio, are to collaborate with the University of Aberdeen as partner on a Scottish research award to assist with critical research to tackle the COVID-19 pandemic.
Caroline Barelle, CEO of Elasmogen commented;
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
1. You could lose all the money you invest
2. You are unlikely to be protected if something goes wrong
3. You won’t get your money back quickly
4. Don’t put all your eggs in one basket
5. The value of your investment can be reduced
If you are interested in learning more about how to protect yourself, visit the FCA’s website here. [https://www.fca.org.uk/investsmart]
